• Folding@home announced it had crossed the exaFLOP barrier, achieving >10¹⁸ operations s⁻¹—roughly 10× the performance of IBM Summit—thanks to a surge of volunteer compute power during the early COVID-19 pandemic.  
• Participants debated whether emergency “temporary” deregulation of drug development was justified; one camp argued that any exemption would merely paper over systemic FDA failures, while another countered that withholding life-saving tools during an exponential outbreak punishes the public, not regulators.  
• Convalescent plasma therapy was discussed as a stop-gap: although clinicians have used recovered-patient plasma, supply will be dwarfed by demand in an exponential epidemic, and large-scale monoclonal antibody production is bottlenecked by existing bioreactor commitments and multi-month cell-line development timelines.  
• A conceptual framing was offered that “humanity is a massively parallel supercomputer” in which every immune system runs independent experiments; banking and sequencing the antibody repertoires of recovered patients could accelerate both basic science and rapid therapeutic design.  
• The channel linked to external commentary (kanzure’s tweet and a Capitalism Magazine article) arguing that the FDA’s regulatory regime should be permanently dismantled rather than granted ad-hoc waivers, labeling the agency the “Federal Death Agency” for delays that cost lives.